|
Epilepsy
|
0.100 |
Biomarker
|
disease |
BEFREE |
Indeed, many genes, including genes encoding drug transporters (ABCB1), drug targets (SCN1A), drug-metabolizing enzymes (CYP2C9, CYP2C19), and human leucocyte antigen (HLA) proteins, may regulate the mechanisms of drug resistance in epilepsy.
|
29804481 |
2018 |
|
Epilepsy
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We aimed to explore the possible influence of CYP2C9 (*2, *3 and IVS8-109 A>T), CYP2C19 (*2, *3 and *17) and ABCB1 (1236C>T, 2677G>A/T and 3435C>T) on phenytoin (PHT) plasma concentrations in 64 Mexican Mestizo (MM) patients with epilepsy currently treated with PHT in mono- (n=25) and polytherapy (n=39).
|
26122019 |
2016 |
|
Epilepsy
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The aim of this study was to retrospectively evaluate the relationship between CYP2C19 polymorphisms and the efficacy of low-dose, add-on CLB therapy in Japanese patients with epilepsy.
|
25323806 |
2015 |
|
Epilepsy
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Effects of CYP2C19 and P450 oxidoreductase polymorphisms on the population pharmacokinetics of clobazam and N-desmethylclobazam in japanese patients with epilepsy.
|
24345815 |
2014 |
|
Epilepsy
|
0.100 |
Biomarker
|
disease |
BEFREE |
In a further multivariate analysis, variants in SCN1A, CYP2C9, CYP2C19 and ABCB1 genes were significantly associated with CDRs of PHT under adjustment of age, gender and epilepsy classifications (adjusted r(2) = 20.07%).
|
22966884 |
2012 |
|
Epilepsy
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study we aimed to investigate the relationship between the genetic polymorphism of cytochrome P450 genes, namely CYP2C9 and CYP2C19 with multiple drug resistance in epilepsy patients.
|
21985811 |
2011 |
|
Epilepsy
|
0.100 |
Biomarker
|
disease |
BEFREE |
We have investigated the association between polymorphisms related to antiepileptic drug metabolism (CYP2C9, CYP2C19, and UGT), transport (ABCB1), and targets (SCN1A) both in a crude analysis and after adjusting by clinical factors associated with drug-resistance, and stratifying by patient age or aetiology of epilepsy.
|
20064729 |
2010 |
|
Epilepsy
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A total of 221 pediatric or adolescent Caucasian patients with epilepsy (105 females; age: 14.5+/-6.54 years) were genotyped for nine putatively functionally relevant ABCB1, ABCC2, CYP2C8, CYP2C9, and CYP2C19 polymorphisms.
|
19415824 |
2009 |
|
Epilepsy
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A nonlinear mixed-effect modeling (NONMEM) program was used to evaluate the effects of cytochrome P450 (CYP) 2C9 and CYP2C19 polymorphisms on the phenobarbital (PB) population clearance for Japanese epileptics.
|
17304159 |
2007 |
|
Epilepsy
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The aim of this study was to clarify the effect of genetic polymorphisms of CYP2C19 on the pharmacokinetics of phenobarbitone (PB) using a nonlinear mixed-effects model (NONMEM) analysis in Japanese adults with epilepsy.
|
10805060 |
2000 |
|
Epilepsy
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The genotype of CYP2C9 (Arg144/Cys, Ile359/Leu) and CYP2C19(*1, *2 or *3) in 134 Japanese adult patients with epilepsy treated with PHT were determined, and their serum concentrations of 5-(4-hydroxyphenyl)-5-phenylhydantoin (p-HPPH) enantiomers, being major metabolites of PHT, were measured.
|
9860067 |
1998 |
|
Epilepsy
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Genetic polymorphism of the CYP2C subfamily and its effect on the pharmacokinetics of phenytoin in Japanese patients with epilepsy.
|
9333104 |
1997 |
|
Epilepsy
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Effect of CYP2C polymorphisms on the pharmacokinetics of phenytoin in Japanese patients with epilepsy.
|
8874828 |
1996 |